- €3.45bn
- €4.02bn
- €1.20bn
Brief: Diasorin Q3 Adj. EBITDA At EUR 94 Mln
Italy - Factors to watch on November 5
Europe Research Roundup: Ashmore, Biomerieux, Diasorin
Europe Research Roundup: Adyen NV, Beazley, Nel ASA
DiaSorin raises 2024 guidance slightly following Q2 results (updated)
DiaSorin slightly raises 2024 guidance following Q2 results
Brief: Diasorin Q2 Adj EBITDA At EUR 102 Mln
Italy - Factors to watch on July 29
Diasorin rises on new product clearance from U.S. FDA
Brief: Diasorin Obtains FDA 510(K) Clearance For Its Liaison Plex Yeast Blood Culture Assay
Europe Research Roundup: ABB Ltd, Capital & Regional Plc, Neste Oyj
Italy - Factors to watch on May 13
Brief: Diasorin CEO hails Q1 performance in China, back to regular business after COVID
Brief: Diasorin Q1 Adj. EBITDA Down To EUR 97 Mln
Italy - Factors to watch on May 10
Barclays starts Biomerieux at 'overweight,' notes smoother growth among peers
Barclays cites DiaSorin's in-line top-line but 'ambitious' margins - starts at 'equal weight'
Europe Research Roundup: Arkema, Fuller Smith & Turner, Siemens Energy
Italy - Factors to watch on April 24